An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.
NIH: National Institute of Diabetes and Digestive and Kidney Diseases
NIDDK Central Repository
Search
Filters

Study Acronym

HALT PKD

1 - 33 of 33 Results
  • 1
Page
Show:
Study Search Results Table
Title
PMID
PMCID
Public Release Type
Publication Year
DOI
Study Acronym
Study Network
Request ID(s)
Public Release Origin
ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing29203126PMC6267804Journal201810.1053/j.ajkd.2017.09.008HALT PKD20790Secondary Research
Acute treatment effects on GFR in randomized clinical trials of kidney disease progression.34862238Journal202210.1681/ASN.2021070948HALT PKD21181Secondary Research
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease29290310PMC5826779Journal201710.1016/j.kint.2017.09.027HALT PKD20790Secondary Research
CD8+ T cells modulate autosomal dominant polycystic kidney disease progression30249452PMC6319903Journal201810.1016/j.kint.2018.06.025HALT PKD20959Secondary Research
Change in albuminuria and GFR slope as joint surrogate endpoints for kidney failure - Implications for phase 2 clinical trials in chronic kidney disease36918388Journal202310.1681/ASN.0000000000000117HALT PKD21181Secondary Research
Collagen IV Gene Mutations in Adults With Bilateral Renal Cysts and CKD31922066PMC6943786Journal201910.1016/j.ekir.2019.09.004HALT PKD21532, 21588, 21748Secondary Research
Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.31874800PMC7218796Journal202010.1016/j.kint.2019.08.038HALT PKD20790, 20959, 21225, 21507, 22080Secondary Research
Development of a Clinical Trial Enrichment (CTE) Tool for Autosomal Dominant Polycystic Kidney DiseaseConference Presentation2023CRISP, HALT PKD22905Secondary Research
Effects of Tolvaptan on Kidney Function Decline in Patients Aged >55 Years With Autosomal Dominant Polycystic Kidney Disease: Pooled Data AnalysisJournal202310.1016/j.xkme.2023.100639CRISP, HALT PKD21540Secondary Research
Ganetespib limits ciliation and cystogenesis in autosomal-dominant polycystic kidney disease (ADPKD)29401581PMC5901382Journal201810.1096/fj.201700909RHALT PKD21532, 21588Secondary Research
Impact of early glomerular filtration rate decline in response to antihypertensive treatment on risk of end-stage kidney disease and cardiovascular outcomes: a systematic review and meta-analysis34930868Journal202210.1097/HJH.0000000000003066HALT PKD23180Secondary Research
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease.33305291PMC7725226Journal202010.34067/KID.0001692020HALT PKD20790, 20959Secondary Research
KIDNEY FUNCTION DECLINE IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS: ASSESSMENT OF TOLVAPTAN'S REAL WORLD EFFECTIVENESSConference Presentation2023CRISP, HALT PKD21540Secondary Research
KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.32541154PMC7384479Journal202010.1159/000508051HALT PKD20959, 22080Secondary Research
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.30922668PMC6478515Journal201910.1016/j.kint.2018.12.023HALT PKD20790Secondary Research
Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.29854969PMC5976807Journal201810.1016/j.ekir.2017.12.011HALT PKD20790Secondary Research
Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype.34890546PMC8764120Journal202210.1016/j.ajhg.2021.11.016HALT PKD21225Secondary Research
Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease.27259053PMC4908191Journal201610.1016/j.ajhg.2016.05.004HALT PKD20790, 21225Secondary Research
Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.29118087PMC5791072Journal201810.1681/ASN.2017070819HALT PKD20790, 20959Secondary Research
Overweight and Obesity and Progression of ADPKD34117082PMC8216617Journal202110.2215/CJN.16871020HALT PKD20959, 22080Secondary Research
POOLED DATA ANALYSIS OF THE EFFECT OF TOLVAPTAN IN PATIENTS AGED 18-35 YEARS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASEConference Presentation2023CRISP, HALT PKD21540Secondary Research
Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies.34401721PMC8350824Journal202110.1016/j.xkme.2021.03.004HALT PKD20790, 20959, 22080Secondary Research
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.30803434PMC6388487Journal201910.1186/s12882-019-1249-6HALT PKD20790, 21328Secondary Research
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.26823553PMC5004648Journal201610.1681/ASN.2015050583HALT PKD20790Secondary Research
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD.36204243PMC9529969Journal202210.1016/j.xkme.2022.100538HALT PKD20790, 20997Secondary Research
The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.29395486PMC6057824Journal201810.1053/j.ajkd.2017.11.015HALT PKD21225, 21507Secondary Research
The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression36422996PMC9870090Journal202310.1172/jci.insight.154773HALT PKD20959, 22080Secondary Research
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.32634120PMC7455088Journal202010.1172/jci.insight.138724HALT PKD20790Secondary Research
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.37250503PMC10220412Journal202310.1016/j.xkme.2023.100639HALT PKD21540Secondary Research
Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease30228110PMC6218833Journal201810.2215/CJN.05850518HALT PKD20959Secondary Research
Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.35217526PMC8975034Journal202210.2215/CJN.08660621HALT PKD20790Secondary Research
Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease35059607PMC8760407Journal202110.1016/j.isci.2021.103697HALT PKD20959, 22080Secondary Research
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International35134221PMC9035348Journal202210.1093/ndt/gfab312HALT PKD21225Secondary Research
  • 1
Page